Modified-Release Drug Delivery Technology
Language: English
Published by CRC Press, 2008
- Hardcover
- New
Condition: New
£ 252.82
Quantity: Over 20 available
Add to basketItem description from seller
MICHAEL J. RATHBONE is Director, Research and Development, and General Manager of InterAg, a Division of DEC International NZ Limited, Hamilton, New Zealand. Dr. Rathbone received his Ph.D. in Pharmaceutical Science from the University of Aston, Birmingh.
Seller Inventory # 595754293
- Title
- Modified-Release Drug Delivery Technology
- Publisher
- CRC Press
- Publication year
- 2008
- Condition
- New
- Binding
- Gebunden
- Language
- English
- ISBN 10
- 1420053558
- ISBN 13
- 9781420053555
- Edition
- 2nd Edition
This two volume Second Edition describes the anatomical, physiological, pharmaceutical, and technological aspects of delivery routes, found in areas like:
- Oral
- Ocular
- Dermal and transdermal
- Vaginal
- Colonic
- Oral mucosal
- Nasal
- Pulmonary
Providing insight and critical assessment of the many available and emerging modified release drug delivery systems for their current and future value, topics include:
- modified drug release landscape; academic, regulatory, and intellectual property viewpoints
- I-vation Sustained Release Intravitreal System
- ViaNase Intranasal Device and controlled particle dispersion technology Platform
- Microneedles for drug delivery, PassPort system, Dot-Matrix technology, ultrasound, iontophoretic and technologies, DiretcHaler Nasal technology, intravaginal ring systems, Supravail, Vagisite, C-Vad™ Vaginal Insert, and ‘Smart’ Vaginal Delivery Systems
- the AERx® Pulmonary Drug Delivery System
- AAD-Adaptive aerosol delivery technology
- nebulizer technologies and dry powder inhaler systems
"Synopsis" may belong to another edition of this title.
About the Author
MICHAEL J. RATHBONE is Director, Research and Development, and General Manager of InterAg, a Division of DEC International NZ Limited, Hamilton, New Zealand. Dr. Rathbone received his Ph.D. in Pharmaceutical Science from the University of Aston, Birmingham, England, and has innovated many novel modified-release drug delivery systems, several of which have been commercialized. Dr. Rathbone has written over 35 peer-reviewed articles, has licensed five US patents and has edited or co-edited three books and numerous special issues of journals.
JONATHAN HADGRAFT is Professor of Biophysical Chemistry, University of London, United Kingdom. Dr. Hadgraft received his D.Phil. in Chemistry and his D.Sc. in Medicine from the University of Oxford, United Kingdom. His major research interests are in the application of physical chemistry to drug delivery, with special reference to the skin. He has been elected to Fellowships of the Royal Society of Chemistry and the American Association of Pharmaceutical Scientists, and has contributed to over 500 publications. He has contributed numerous book chapters and has co-edited several books. He serves on a number of editorial boards of pharmaceutical science journals.
MICHAEL S. ROBERTS is Professor, School of Medicine, University of Queensland, Brisbane, Australia; Senior Principal Research Fellow, National Health and Research Council; Director Therapeutics Research Unit, Princess Alexandra Hospital, Queensland Australia; Adjunct Professor, University of Canberra, Australia; and Visiting Professor, University of Lyon, France. Dr. Roberts received his Ph.D. and D.Sc. from the University of Sydney, Australia, and his M.B.A. from the University of Queensland. Dr. Roberts has also written over 280 peer-reviewed articles, 36 chapters, and has edited or co-edited five books.
MAJELLA E. LANE is a lecturer in Pharmaceutics in the School of Pharmacy, University of London, United Kingdom. She received her Ph.D. from Trinity College, Dublin, Ireland, and spent a sabbatical period at the University of Michigan, Ann Arbor, where she holds a Visiting Associate Scientist appointment. Her current research interests include development of vaccine dosage forms, formulation of peptides, transdermal drug delivery and mucosal drug delivery, and modeling of absorption processes across epithelial barriers.
"About the title" may belong to another edition of this title.
Shipping rates from Germany to U.S.A.
| Item | 26 to 60 business days | 26 to 60 business days |
|---|---|---|
| First item | £ 41.47 | £ 41.47 |
Payment methods
- Bank Wire Transfer
- Check
- Paypal
Store description
Online Handel nur mit Neubüchern
Seller's business information
Moluna GmbH
Engberdingdamm 27
Greven, Germany 48268
Terms of sale
About Us
Legal website operator identification:
Moluna GmbH
Represented by the general manager Helge Blischke
Engberdingdamm 27
48268 Greven
Germany
Telephone: 02571/5698933
Telefax: 02571/5698930
E-Mail: abe@moluna.de
VAT No.: DE296281834
listed in the commercial register of the local court Steinfurt
Commercial register number - Part B of the commercial register - 10553
We are a member of the initiative „FairCommerce“ since 24.07.2015.
For more information, see: www.haendlerbund.de/faircommerce.
Right of withdrawal
If you are a consumer you can withdraw from the contract in accordance with the following. Consumer means any natural person who is acting for purposes which are outside his trade, business, craft or profession.
Information regarding the right of withdrawal
Statutory right to withdraw
You have the right to withdraw from this contract within 14 days without giving any reason.
The withdrawal period will expire after 14 days from the day on which you acquire, or a third party other than the carrier and indicated by you acquires, physical possession of the last good or the last lot or piece.
To exercise the right of withdrawal, electronically fill in and submit a clear statement on our website, under "My Purchases" in "My Account". We will communicate to you an acknowledgement of receipt of such a withdrawal on a durable medium (e.g. by e-mail) without delay.
To meet the withdrawal deadline, it is sufficient for you to send your communication concerning your exercise of the right of withdrawal before the withdrawal period has expired.
Effects of withdrawal
If you withdraw from this contract, we will reimburse to you all payments received from you, including the costs of delivery (except for the supplementary costs arising if you chose a type of delivery other than the least expensive type of standard delivery offered by us).
We may make a deduction from the reimbursement for loss in value of any goods supplied, if the loss is the result of unnecessary handling by you.
We will make the reimbursement without undue delay, and not later than 14 days after the day on which we are informed about your decision to withdraw from this contract.
We will make the reimbursement using the same means of payment as you used for the initial transaction, unless you have expressly agreed otherwise; in any event, you will not incur any fees as a result of such reimbursement.
We may withhold reimbursement until we have received the goods back, or you have supplied evidence of having sent back the goods, whichever is the earliest.
You shall send back the goods or hand them over to moluna, Greven, Germany, without undue delay and in any event not later than 14 days from the day on which you communicate your withdrawal from this contract to us. The deadline is met if you send back the goods before the period of 14 days has expired. You will have to bear the direct cost of returning the goods. You are only liable for any diminished value of the goods resulting from the handling other than what is necessary to establish the nature, characteristics and functioning of the goods.
Exceptions to the right of withdrawal
The right of withdrawal does not apply to:
- The delivery of newspapers, journals or magazines with the exception of subscription contracts; and
- The supply of digital content which is not supplied on a tangible medium (e.g. on a CD or DVD) if you accepted when you placed your order that we could start to deliver it, and that you could not withdraw once delivery had started.